RxDoctor Payments Data

George Groussis, MD

Internal Medicine · Worcester, MANPI 1184690992

Payments from drug & device makers

$4,938in general payments, 2019–2025

Across 227 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$580
  • Exact Sciences$457
  • Pfizer$327
  • Boehringer Ingelheim$316
  • Johnson & Johnson$245
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,938100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,938 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$114,681
Medicare patients
172
Services billed
1,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$86,080
FarxigaDapagliflozin Propanediol63$68,383
OzempicSemaglutide50$67,562
JardianceEmpagliflozin52$56,443
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$51,411
MounjaroTirzepatide35$41,479
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$19,477
WegovySemaglutide13$17,142
Atorvastatin Calcium403$7,129
Rosuvastatin Calcium127$5,530
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$5,088
Metoprolol Succinate168$3,595
Famotidine230$3,215
Omeprazole154$2,991
Amlodipine Besylate376$2,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,828$87,86088 claims
PfizerEliquis$327$86,08084 claims
Novo NordiskOzempic, Wegovy$178$84,70463 claims
Boehringer IngelheimJardiance$316$56,44352 claims
GSKTrelegy Ellipta$93$51,41169 claims
Lilly USA, LLCMounjaro$580$41,47935 claims
AbbVieSynthroid$91$66030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →